Medical
UK
Europe
NovoCure
$50.009876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$50.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.14 (0.28%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell NovoCure and other stocks, options, ETFs, and crypto commission-free!
About
NovoCure Limited Ordinary Shares, also called NovoCure, is global oncology company, which engages in the development and commercialization of its innovative therapy. It focuses on the commercial adoption of Optune, and its Tumor Treating Fields delivery system, for the treatment of glioblastoma (GBM), and to advance programs testing the efficacy and safety of Optune in multiple solid tumor indications through clinical pipeline. Read More The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Employees
598
Headquarters
St. Helier, Jersey
Founded
2000
Market Cap
4.65B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
829.59K
High Today
$51.44
Low Today
$49.53
Open Price
$49.53
Volume
243.76K
52 Week High
$56.67
52 Week Low
$19.55
Collections
Medical
UK
Europe
Health
Cancer Prevention
Technology
2015 IPO
News
Markets Insider20h
Novocure Announces 48 Presentations and a Symposium Session on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2019
NovoCure (NASDAQ: NVCR) announced today 48 presentations on Tumor Treating Fields at the American Association for Cancer Research (AACR) Annual Meeting 2019, March 29 through April 3, in Atlanta.
Seeking Alpha20h
Novocure’s Chief Science Officer retires
Novocure (NASDAQ:NVCR) Chief Science Officer and Head of R&D, Dr. Eilon Kirson will retire effective May 1, to spend more time with his family.
Markets Insider21h
Novocure’s Chief Science Officer Retires after 17 Years of Service
NovoCure (NASDAQ: NVCR) today announced the retirement of Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development, effective May 1, 2019. Dr. Kirson will step away from the healthcare industry and frequent international travel to spend more time with his family.
Price Paid on Robinhood
61% Higher
Right Now
52 Week Low
$19.55
Average Price Paid
$31.10
52 Week High
$56.67
Earnings
-$0.24
-$0.20
-$0.15
-$0.11
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected Apr 25, Pre-Market